NeRRe Therapeutics Ltd.   Report issue

For profit Phase 1 Phase 2
Founded: Stevenage United Kingdom (2012)
Status: Acquired by Bayer (2020)

Organization Overview

First Clinical Trial
2016
NCT02865538
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Nerre Therapeutics Ltd.

Active Ingredients

Drugs in Phase 2 Trials (2)

nt-814 (3 trials)

orvepitant (5 trials)

Drugs in Phase 1 Trials (1)

itraconazole (sporanox) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cough (Phase 2)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Hot Flashes (Phase 2)

Pruritus (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial APIs: 3